Skip to main
RNXT

RenovoRx (RNXT) Stock Forecast & Price Target

RenovoRx (RNXT) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

RenovoRx Inc. has demonstrated notable revenue growth in Q2, with revenue increasing to $422,000 from $197,000 in Q1, indicating positive momentum in its financial performance. The company is anticipated to experience significant revenue growth, projected to reach $1.3 million in 2025 and further increase to $4.5 million in 2026, reflecting a strong potential for scalability in its market. As a clinical-stage biopharmaceutical company with a focus on innovative therapies for cancer treatment, RenovoRx's strategic position and proprietary technology may enhance its capacity to meet high unmet medical needs, suggesting a favorable outlook for future financial performance.

Bears say

RenovoRx's financial performance reflects a troubling pattern, with reported revenue of only $0.3 million to $0.4 million against a net loss of $2.9 million and an earnings per share (EPS) of $(0.08), aligning closely with earlier estimates but revealing a lack of growth. The company's operational challenges are underscored by limited revenue generation amid high costs, which raises red flags regarding its sustainability in the competitive biopharmaceutical sector. Furthermore, the context of developing therapies for pancreatic cancer, which exhibits a notably low 5-year survival rate of 12%, emphasizes the heightened risk associated with the firm's pursuit of a narrow market with significant unmet needs.

RenovoRx (RNXT) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of RenovoRx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About RenovoRx (RNXT) Forecast

Analysts have given RenovoRx (RNXT) a Strong Buy based on their latest research and market trends.

According to 2 analysts, RenovoRx (RNXT) has a Strong Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

RenovoRx (RNXT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.